A Study of Guselkumab in Participants With Familial Adenomatous Polyposis | oneFAPvoice

welcome to oneFAPvoice

- a positively charged Familial Adenomatous Polyposis community.
  • join today!
recruiting

A Study of Guselkumab in Participants With Familial Adenomatous Polyposis

study id #: NCT03649971

condition: Adenomatous Polyposis Coli

status: recruiting

purpose:

The purpose of this study is to determine the effect of treatment with guselkumab in participants with familial adenomatous polyposis (FAP) on rectal/pouch polyp burden.

intervention: Guselkumab, Placebo

start date: November 19, 2018

estimated completion: August 31, 2020

last updated: August 15, 2019

phase of development: Phase 1

size / enrollment: 72

primary outcomes:

  • Percentage Change from Baseline in Rectal/pouch Polyp Burden at Week 24 [ Time Frame: Baseline, Week 24 ]
    Percentage change from baseline in rectal/pouch polyp burden (sum of the polyp diameters) at Week 24 will be determined through endoscopy.

secondary outcomes:

  • Percentage Change from Baseline in Number of Colorectal Polyps [ Time Frame: Baseline, Weeks 24 and 52 ]
    Percentage change from baseline in number of colorectal polyps will be determined.
  • Percentage Change from Baseline in Number of J-pouch Polyps [ Time Frame: Baseline, Weeks 24 and 52 ]
    Percentage change from baseline in number of J-pouch polyps will be determined.
  • Percentage Change from Baseline in J-pouch Polyp Burden [ Time Frame: Baseline, Weeks 24 and 52 ]
    Percentage change from baseline in J-pouch polyp burden (sum of polyp diameters) will be determined.
  • Percentage Change from Baseline in Number of Duodenal Polyps [ Time Frame: Baseline, Weeks 24 and 52 ]
    Percentage change from baseline in number of duodenal polyps will be determined.
  • Percentage Change from Baseline in Duodenal Polyp Burden [ Time Frame: Baseline, Weeks 24 and 52 ]
    Percentage change from baseline in duodenal polyp burden (sum of polyp diameters) will be determined.
  • Change in International Society for Gastrointestinal Hereditary Tumors (InSiGHT) Stage [ Time Frame: Baseline, Weeks 24 and 52 ]
    Change in InSiGHT stage will be determined. Various stages of InSiGHT staging system are defined as: Stage 0: 0-10 polyps, all less than (<)5 millimeter (mm); Stage 1: 10-25 polyps, most < 5 mm, none greater than (>) 1 centimeter (cm); Stage 2: 10-25 polyps, any > 1 cm, amenable to complete removal; Stage 3: > 25 polyps amenable to complete removal, or any incompletely removed sessile polyp, or any evidence of High-Grade Dysplasia (HGD), even if completely excised; and Stage 4: > 25 polyps amenable to complete removal, or any incompletely excised sessile polyp showing HGD, any invasive cancer).
  • Change in Spigelman Stage Score [ Time Frame: Baseline, Weeks 24 and 52 ]
    Change in Spigelman stage score will be determined. Spigelman classification system measures risk of developing duodenal cancer in familial adenomatous polyposis (FAP). It has been classified in following stages- Stage 0 (0 points); Stage 1 (1-4 points); Stage 2 (5-6 points); Stage 3 (7-8 points); and Stage 4 (9-12 points). The total score ranges from 0 to 12. Points are accumulated for polyps' number, size, histology and severity of dysplasia. Stage 1 indicates mild disease, whereas stage 3-4 indicates severe duodenal polyposis.
  • Trough Concentration of Guselkumab [ Time Frame: Weeks 0, 4, 8, 12, 16, 20, and 24 ]
    Serum samples will be analyzed to determine trough concentrations of guselkumab using a validated specific, and sensitive method.
  • Number of Participants with Anti-guselkumab Antibodies [ Time Frame: Weeks 0, 4, 8, 12, 16, 20, and 24 ]
    Number of participants with Anti-guselkumab antibodies will be determined.
  • Anti-guselkumab Antibodies Serum Titers [ Time Frame: Weeks 0, 4, 8, 12, 16, 20, and 24 ]
    Serum samples will be screened for antibodies binding to guselkumab and the titer of confirmed positive samples will be reported.
  • Number of Participants with Adverse Events as a Measure of Safety [ Time Frame: From Screening up to 52 Weeks ]
    An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.
  • Number of Participants with Vital Sign Abnormalities as a Measure of Safety and Tolerability [ Time Frame: From Screening up to 24 Weeks ]
    Number of participants with vital sign abnormalities will be reported. Vital signs includes temperature, pulse/heart rate, respiratory rate and blood pressure.
  • Number of Participants with Clinical Laboratory Abnormalities as a Measure of Safety and Tolerability [ Time Frame: From Screening up to 24 Weeks ]
    Number of participants with clinical laboratory abnormalities will be reported. Blood samples for serum chemistry and hematology will be collected at predefined time points for clinical laboratory testing.
  • Relative Changes to Baseline in Levels of Interleukin (IL)-23 Effector Proteins in Biopsy Tissue [ Time Frame: Baseline, Weeks 12 and 24 ]
    Relative Changes to Baseline in levels of IL-23 effector proteins in biopsy tissue will be measured.

inclusion criteria:
• Phenotypic familial adenomatous polyposis (FAP) with disease involvement of the colorectum by either genetic or clinical diagnosis: Adenomatous polyposis coli (APC) germline mutation with or without family history, or with greater than (>)100 adenomas in large intestine and a family history of FAP, attenuated FAP is allowed. FAP phenotype post colectomy for polyposis with a family history of FAP may be allowed
• Post-colectomy or subtotal colectomy
• Polyps with a sum of diameters greater than or equal to (>=)10 millimeter (mm) in the rectum or pouch on biopsy at screening
• A woman of childbearing potential must agree not to get pregnant during the study and at least 12 weeks after the last dose of study administration
• A woman must agree not to breast feed or donate eggs (ova, oocytes) during the study and for a period of 12 weeks after the last administration of study drug

exclusion criteria:
• Prior use of any biologic therapy targeting interleukin (IL)-12/23, IL-17, or IL-23 receptor
• Use of non-steroidal anti-inflammatory drugs other than aspirin during the study. The use 81 milligram (mg) of aspirin a day or 650 mg of aspirin per week is allowed
• Treatment with other FAP-directed drug therapy (including NSAID [Nonsteroidal anti-inflammatory drug] drugs), unless completes a 4-week washout period prior to randomization
• Duodenum or colon/rectum/pouch with high grade dysplasia or cancer on biopsy at screening
• Duodenal, colorectal, or pouch polyp >1 centimeter (cm) not excised at the screening evaluation

sponsor: Janssen Research & Development, LLC

contacts: Study Contact: 844-434-4210, JNJ.CT@sylogent.com

investigators: Janssen Research & Development, LLC Clinical Trial

investigators: Janssen Research & Development, LLC Clinical Trial

locations: United States, Netherlands, Puerto Rico

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close